Oncotelic Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	0.07	-	-
Gross Profit	-	-	0.07	-	-
Selling, General & Admin	2.98	0.38	0.57	4.85	5.47
Research & Development	0	-	0.06	0.76	3.66
Operating Expenses	2.99	0.38	0.63	5.61	9.13
Operating Income	-2.99	-0.38	-0.56	-5.61	-9.13
Interest Expense	-0.89	-0.86	-1.04	-2.97	-2
Other Non Operating Income (Expenses)	0.36	-0.26	-0.15	0.68	0.29
EBT Excluding Unusual Items	-3.51	-1.49	-1.76	-7.91	-10.84
Impairment of Goodwill	-	-3.2	-6.08	-4.11	-
Gain (Loss) on Sale of Investments	365.35	-	0.01	-	-
Gain (Loss) on Sale of Assets	-	-	-	16.95	-
Legal Settlements	-0.2	-	-	-	-
Other Unusual Items	-1.06	-0.09	-0.37	-0.26	0.32
Pretax Income	360.57	-4.78	-8.21	4.68	-10.52
Income Tax Expense	111.55	-	-	-	-
Earnings From Continuing Operations	249.02	-4.78	-8.21	4.68	-10.52
Minority Interest in Earnings	0.25	0.26	0.3	0.42	1.13
Net Income	249.28	-4.52	-7.9	5.09	-9.39
Net Income to Common	249.28	-4.52	-7.9	5.09	-9.39
Shares Outstanding (Basic)	421	404	384	384	303
Shares Outstanding (Diluted)	421	404	384	457	303
Shares Change (YoY)	4.12%	5.29%	-16.01%	50.89%	244.02%
EPS (Basic)	0.59	-0.01	-0.02	0.01	-0.03
EPS (Diluted)	0.59	-0.01	-0.02	0.01	-0.03
Gross Margin	-	-	100.00%	-	-
Operating Margin	-	-	-806.96%	-	-
Profit Margin	-	-	-11290.13%	-	-
EBITDA	-	-	-0.55	-5.6	-9.06
D&A For EBITDA	-	-	0.01	0.01	0.06
EBIT	-2.99	-0.38	-0.56	-5.61	-9.13
Effective Tax Rate	30.94%	-	-	-	-
Revenue as Reported	-	-	0.07	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.